Most patients inevitably fail this therapy, progressing to castration-recurrent prostate cancer (CR-CaP) typically presenting as bone or lymph node metastases whose growth depends on sustained androgen receptor (AR) signaling [2]. This evidence concerns the gene AR and prostate carcinoma.